BioAtla
selective and targeted cab technology widens therapeutic window | BioAtla
Company
Deck Type
Sector
Industry
Deck date
May 2023
Slide
6 of 44
Similar slides by BioAtla
See diffirences between slides (animation)
Investor Presentation
January 2024
selective and targeted cab technology widens therapeutic window | BioAtla
Investor Presentation
August 2023
selective and targeted cab technology widens therapeutic window | BioAtla
Investor Presentation
November 2022
selective and targeted cab technology widens therapeutic window | BioAtla
Investor Presentation
August 2022
selective and targeted cab technology widens therapeutic window | BioAtla
Related slides by other companies
Genprex
Investor Presentation
October 2022
in small cell lung cancer | Genprex
Genelux
Investor Presentation
October 2023
diversified designs and indications exploit competitive advantages bene | Genelux
Alkermes
Investor Day
March 2021
immune modulation in oncology based on engineered have pleiotropic effects and can act on every phase of the cancer immunity cycle alkermes is focusing on based therapies designed to increase visibility of tumor cells to immune system increase tumor killing potential of and cells mutation fusion remove suppressive signals in the tumor modern based drugs need a high degree of engineering to reduce side effects improve enhance efficacy natural killer journal of cancer cycle | Alkermes
Boundless Bio
IPO
March 2024
amplified cancer cells have significantly elevated replication stress amplified amplified a | Boundless Bio
Other recent decks by BioAtla
See all presentations (8 decks)
Investor Presentation
January 2024
Investor Presentation
August 2023
Investor Presentation
November 2022
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights